78 related articles for article (PubMed ID: 11820605)
1. Study of p53 protein expression in prostate cancer.
Sulik M; Guzińska-Ustymowicz K; Darewicz B; Sulik A
Folia Histochem Cytobiol; 2001; 39 Suppl 2():197-8. PubMed ID: 11820605
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 immunohistochemical detection in prostate cancer.
Sulik M; Guzińska-Ustymowicz K
Rocz Akad Med Bialymst; 2002; 47():254-61. PubMed ID: 12533968
[TBL] [Abstract][Full Text] [Related]
3. Study of P53 protein expression in colorectal cancer.
Sulkowska M; Famulski W; Guzińska-Ustymowicz K; Sulkowski S
Folia Histochem Cytobiol; 2001; 39(2):157-8. PubMed ID: 11374803
[TBL] [Abstract][Full Text] [Related]
4. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
5. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer.
Sulik M; Guzińska-Ustymowicz K
Rocz Akad Med Bialymst; 2002; 47():262-9. PubMed ID: 12533969
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
7. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
9. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
12. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer.
Lin JT; Wang JS; Jiann BP; Yu CC; Tsai JY; Huang JK; Wu TT
J Formos Med Assoc; 2005 Nov; 104(11):864-7. PubMed ID: 16496070
[TBL] [Abstract][Full Text] [Related]
13. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
14. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
[TBL] [Abstract][Full Text] [Related]
15. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients.
Kuczyk M; Machtens S; Hradil K; Schubach J; Christian W; Knüchel R; Hartmann J; Bokemeyer C; Jonas U; Serth J
Br J Cancer; 1999 Nov; 81(6):1052-8. PubMed ID: 10576664
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
18. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]